Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03269552 · ClinicalTrials.gov registry record · Phase 2
Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone Lymphoma
A Phase 2 study, sponsored by University of Washington.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT03269552 is a Phase 2 study that was terminated before completion, run by University of Washington. The registered enrollment target is 4 participants.
The verdict
NCT03269552, a Phase 2 study, was terminated before completion, sponsored by University of Washington.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
This phase II trial studies how well carfilzomib with or without rituximab work in treating patients with Waldenstrom macroglobulinemia or marginal zone lymphoma that is previously untreated, has come back, or does not respond to treatment. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as rituximab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving carfilzomib alone when disease is responding or with rituximab when disease is not responding may work better in treating patients with Waldenstrom macroglobulinemia or marginal zone lymphoma.
Interventions
- OTHER Laboratory Biomarker Analysis
- BIOLOGICAL Rituximab
- DRUG Carfilzomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2017-12-18 |
| Est. Completion | 2018-12-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03269552
The ClinicalTrials.gov registry entry for NCT03269552 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT03269552 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03269552 about?
NCT03269552 is a clinical study titled "Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone Lymphoma". This phase II trial studies how well carfilzomib with or without rituximab work in treating patients with Waldenstrom macroglobulinemia or marginal zone lymphoma that is previously untreated, has come back, or does not respond to treatment. Carfilzomib may stop the growth of cancer cells by blocking...
What is the current status of trial NCT03269552?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2017-12-18. Estimated completion is 2018-12-28.
What interventions are being tested in trial NCT03269552?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Rituximab (BIOLOGICAL), Carfilzomib (DRUG).
Who is sponsoring clinical trial NCT03269552?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.